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In late December 2019, a cluster of pneumonia cases of
unknown cause was first noted in human patients in the city of
Wuhan, Hubei Province, China.1 The patients with this emerging
disease presented with clinical signs of viral pneumonia similar to
those observed in severe acute respiratory syndrome (SARS).1
Chinese scientists, including those in the Shanghai Public Health
Clinical Center, the Chinese Center for Disease Control and Prevention, and the Wuhan Institute of Virology, immediately took
actions to probe for the obligated emerging pathogen(s) through
next-generation sequencing. A novel Betacoronavirus was soon
identified, and its genome sequence was first made accessible to
the world on January 12, 2020.2 On February 11, 2020, this novel
coronavirus was named SARS-coronavirus 2 (SARS-CoV-2) by
the International Committee on Taxonomy of Viruses and the
associated disease was named coronavirus disease 2019
(COVID-19) by the World Health Organization.
COVID-19 is highly contagious. It has been reported that
SARS-CoV-2 had an estimated basic case reproduction number
(R0) as high as 3.15 before the implementation of the emergency
response on January 23, 2020, in mainland China.3 SARS-CoV-2
viral load in the upper respiratory system is highly dynamic along
the progression of COVID-19, and it exhibits significant variation
in different patients,4 with peaks on the order of 108 viral genome
copies/mL in throat swabs and 1011 copies/mL in sputum samples.5 SARS-CoV-2 also showed differential tissue tropism in
different infected individuals. Viral load could be higher in fecal
samples than in nasopharyngeal swab samples in some cases,
likely because of oral transmission.6 The current standard operating procedure in clinical diagnosis uses pharyngeal swabbing
to collect samples from the upper respiratory system. Limitations
in preparing viral genetic materials for PCR tests include timing
of sample collection and anatomic locations of sampling, which
can be further complicated by practical variations in technical
From athe Department of Critical Medicine, Southern Medical University, Guangzhou;
b
the Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge; and cthe Department of Microbiology & Immunology, College of Veterinary Medicine, Cornell University, Ithaca.
Disclosure of potential conflict of interest: W. Huang received research support from
MegaRobo Technologies Corporation. F. Wu declares that she has no relevant conflicts
of interest.
Received for publication April 7, 2020; revised April 16, 2020; accepted for publication
April 17, 2020.
Available online April 25, 2020.
Corresponding author: Feng Wu, MD, 1838 Guangzhou North Avenue, Baiyun District,
Guangzhou, Guangdong 510515, China. E-mail: wishuhappy@126.com. Or Weishan
Huang, PhD, 1909 Skip Bertman Drive, Baton Rouge, LA 70803. E-mail: huang1@
lsu.edu.
J Allergy Clin Immunol 2020;146:64-6.
0091-6749/$36.00
Ó 2020 American Academy of Allergy, Asthma & Immunology
https://doi.org/10.1016/j.jaci.2020.04.015

64

operations such as those in shipping, storage, and material/reagent preparation. The genetic sequence of SARS-CoV-2 enabled
the rapid development of point-of-care real-time PCR diagnostic
tests specific for SARS-CoV-2. PCR tests were used as a criterion
standard measure to confirm active SARS-CoV-2 infection. There
was, however, a false-negative rate close to 40%7 because of
various issues, most of which are associated with sample preparation. This 40% false-negative rate is the rate of PCR testing in
diagnosing SARS-CoV-2 infection, but not the false-negative
rate of PCR test kits. In a recent external quality assessment program directed by the National Center for Clinical Laboratories in
China, SARS-CoV-2 PCR test kits approved by China’s National
Medical Products Administration were reported with an overall
95.4% positive test result when the input viral genomic load
was 3200 copies/mL. The PCR test kit developed by the Beijing
Genomics Institution detected 100% of the positive samples when
the input was 3200 copies/mL and 97.1% of those with input level
at 640 copies/mL; this kit was approved by the US Food and Drug
Administration through emergency use authorization, and it
became available for COVID-19 diagnosis in the United States
on March 26, 2020.
There is a broad spectrum of COVID-19 symptoms, including
fever, dry cough, shortness of breath, sputum production,
diarrhea, fatigue, and others, most of which are associated with
the respiratory and gastrointestinal systems.8 In mainland China,
about 80% of the patients with confirmed infection have mild
symptoms and 2.3% have fatal symptoms, whereas 1.2% are
asymptomatic (calculated on the basis of data reported before
February 11).9 The reported asymptomatic patients here were
defined by a positive PCR test result accompanied by a lack of
symptoms clinically, as described by patients, measured by doctors, and visualized by imaging, and the patients did not develop
any symptoms after a fortnight quarantine. Patients who are still
in the incubation period may remain asymptomatic in their upper
respiratory system for weeks, although signs of pneumonia might
have been developing in their lower respiratory system. There is
evidence that infected individuals can be contagious even when
they show no symptoms,9 and light or mild cases can develop
into severe and even critical cases after a long period of time
on account of lack of rest, mental stress, and/or malnutrition.10
An early and accurate diagnosis is extremely critical for containment and disease intervention, as well as for epidemiologic
investigation.
Some patients in whom the virus was suspected had a clear
history of contacts with confirmed and symptomatic patients but
tested negative by PCR multiple times, whereas their symptoms
varied from signs of viral pneumonia to mild or even no
symptoms. Some patients had a documented history of exposure
and showed typical signs of ground glass opacity in computed
tomography (CT) scans; these patients were immediately
admitted and treated as having COVID-19 with clinical diagnosis
in China, with most of them testing positive by PCR and/or
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FIG 1. Scheme of the COVID-19 diagnostic process in mainland China. In mainland China, patients with any
COVID-19 symptoms and/or a documented history of contact with individuals with a confirmed case of
COVID-19 were examined with CT scanning and PCR testing. Patients were then divided into 3 categories on
the basis of findings in lung imaging. Signs of pneumonia in imaging and a positive PCR test result were
used to diagnose and confirm COVID-19. Patients who had a contact history and typical signs of pneumonia
in imaging but had a negative PCR test results were clinically diagnosed as having COVID-19 and
subsequently retested with PCR and antibody assays. Before February 11, 2020, asymptomatic cases were
reported as COVID-19 in mainland China. In early February, the 4th edition of Diagnosis and Treatment
Protocol for Novel Coronavirus Pneumonia was released in mainland China; it recommended reporting
SARS-CoV-2 infection in 2 categories: (1) COVID-19 (cases with confirmed infection and disease symptoms)
and (2) asymptomatic infection. Any symptoms, including discomfort reported by patients, disease
parameters measured by doctors (eg, high body temperature and low fingertip pulse oximeter reading),
and signs of pneumonia in CT images, will define a case as symptomatic. The current reported COVID-19
cases in mainland China include all cases of COVID-19 (cases involving patients with infection plus
symptoms) and asymptomatic cases (cases involving patients who never had symptoms) of SARS-CoV-2
infection determined before February 11, 2020.

antibody assays during disease progression and recovery. Because
of variations in the viral load of different individuals, and timing
and anatomic locations of sampling for PCR, some infected
patients were tested more than once but never had a sample with
viral load that passed the PCR detection threshold. These patients
with COVID-19 could have fully recovered without any positive
PCR test results. Their immune systems, however, kept the
footprints of the infection, virus-specific antibodies. By testing
for SARS-CoV-2–specific antibodies, it was possible to determine whether the patients in whom the virus was suspected had a
history of infection, even if the virus had been cleared after
recovery. To obtain a more accurate number of COVID-19 cases,
the Chinese Center for Disease Control and Prevention, along
with scientists and doctors, developed a standard operating
procedure for screening patients in whom the virus was suspected
and confirming cases involving patients with infection who
showed negative results in PCR tests by using SARS-CoV-2–
specific antibody assays. A combination of information on
exposure history, clinical presentation visualized on CT scans,
presence of viral genes, and presence of virus-specific antibodies
was used for diagnosing COVID-19 in mainland China. Of
note, in an antibody (IgG) test trial conducted with >600

serum samples collected from >300 patients with ‘‘clinically
diagnosed’’ COVID-19, more than 95% of the samples collected
21 to 25 days after disease onset showed strong positive results
(An et al, data not shown).
The schematic flowchart delineating the standard operating
procedure of the COVID-19 diagnostic process in mainland
China is depicted in Fig 1. In brief, patients in whom COVID19 is suspected and who have exhibited any COVID-19 symptoms and/or have a confirmed history of exposure are first
evaluated by CT scanning and PCR tests for SARS-CoV-2.
These patients are then divided into 3 categories: (1) those
with no signs of pneumonia on their CT scan; (2) those with
atypical signs of lung opacity on their CT scan; and (3) those
with typical signs of viral pneumonia ground glass opacity on
their CT scan. In these 3 categories, patients who have a positive PCR test result are confirmed as having the infection. In
the second category, patients who have atypical signs of lung
opacity on their CT scan and a negative test result by PCR
will be retested with PCR and antibody assays. In the third
category, patients who have a documented history of exposure
and have shown signs of typical viral pneumonia on their CT
scan are reported as having a ‘‘clinically diagnosed case of
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COVID-19.’’7 In February, in Hankou Hospital in the city of
Wuhan, an antibody test trial with serum samples collected
from more than 300 ‘‘clinically diagnosed’’ patients showed
that over 95% of these patients had a history of infection (An
et al, data not shown); therefore, it is unlikely that clinical diagnosis would lead to an overestimation of COVID-19 cases in
mainland China. On the basis of this scheme of diagnostic process as analyzed and published by the Chinese Center for Disease Control and Prevention, by February 11, 2020, there were
72,314 patients with COVID-19 reported in mainland China, of
whom 1.2% were asymptomatic, 61.8% showed signs of pneumonia with a positive PCR result, and 14.6% were clinically
diagnosed (Fig 1).10 In early February, mainland China started
to report asymptomatic cases of SARS-CoV-2 infection and
COVID-19 (infection plus disease symptoms) separately, according to the fourth edition of the Diagnosis and Treatment
Protocol for Novel Coronavirus Pneumonia. Antibody assays
were adopted to retest suspected cases involving patients who
tested negative by PCR assay, and by March 31, 2020, a total
of 81,554 confirmed cases of COVID-19 in mainland China
were reported by the National Health Commission of China.
The goal of this Editorial is to provide a concise and clear
flowchart to depict the COVID-19 diagnostic process developed
and implemented in mainland China. We hope that this helps
our readers better understand how the math was done to
determine the number of reported cases of SARS-CoV-2
infection in mainland China. The math that results in the
reported number of confirmed cases in mainland China is
clearly beyond pneumonia. Despite our general understanding
that COVID-19 is an acute respiratory disease caused by a novel
coronavirus, clinical diagnosis was often complicated by
clinical presentations, individual variations in patients and
medical/laboratory operators, and the sensitivity and specificity
of the tests. This diagnostic process used in mainland China
may not be directly applicable to other areas in the world during
the COVID-19 pandemic; however, it exploited current knowledge of epidemiology, disease characteristics, viral genetics,
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and immunology about COVID-19, and it provides an example
of a comprehensive diagnostic approach.
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